Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

A U.S. appeals court on Friday revived more than 500 lawsuits alleging that Merck & Co failed to warn that its osteoporosis ...

(Reuters) - A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the ...

The Pan American Health Organisation has launched a partnership with Merck & Company to improve health care and maternal health outcomes for women ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

The U.S. SEC settled charges against Philip Markin, a fifth person charged in connection with an insider trading scheme involving the February 2021 $1.85 billion offer by Merck & Co. Inc. to acquire ...

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...